Destiny Pharma Initiates Research to Explore XF Drug Potential for CF

Brighton, UK – Destiny Pharma, a clinical-stage biotechnology company, has launched a research project to evaluate its XF-73 drug for treating MRSA infections in cystic fibrosis (CF) patients. Supported by the U.S. Cystic Fibrosis Foundation, the study aims to measure the drug's effectiveness against MRSA isolates from CF patients' lungs in the United States.

The research will be conducted at the CF Foundation National Resource Center for Microbiology at Seattle Children's Hospital, focusing on 33 MRSA isolates and examining the impact of mucus on XF-73's activity. CF affects nearly 40,000 individuals in the U.S. and 105,000 worldwide, leading to significant respiratory complications. MRSA infections, found in over 15% of CF patients, are resistant to multiple antibiotics.

This initiative builds on previous studies demonstrating XF-73's superior activity compared to mupirocin against MRSA in skin infections and its efficacy against MRSA isolates globally. Further data on XF-73's effectiveness in preventing bloodstream infections will be presented at the Infection Prevention Society Conference.